Enhancing human cardiomyocyte differentiation from induced pluripotent stem cells with trichostatin A

Shiang Y. Lim, Priyadharshini Sivakumaran, Duncan E. Crombie, Gregory J. Dusting, Alice Pébay, Rodney J. Dilley

    Research output: Chapter in Book/Conference paperChapterpeer-review

    4 Citations (Scopus)

    Abstract

    © Springer Science+Business Media New York 2014. Human induced pluripotent stem (iPS) cells are a promising source of autologous cardiomyocytes to repair and regenerate myocardium for treatment of heart disease. In this study, we describe a method for enhanced cardiomyocyte production from human iPS cells by treating embryoid bodies with a histone deacetylase inhibitor, trichostatin A (TSA), together with activin A and bone morphogenetic protein (BMP)-4. The resulting cardiomyocytes expressed cardiac-specific transcription factors and contractile proteins at both gene and protein levels. Functionally, the contractile embryoid bodies (EBs) displayed calcium cycling and were responsive to the chronotropic agents isoprenaline (0.1 μM) and carbachol (1 μM). The cardiomyocytes derived from human iPS cells may be used to engineer functional cardiac muscle tissue for studying pathophysiology of cardiac disease, for drug discovery test beds, and potentially for generation of cardiac grafts to surgically replace damaged myocardium.
    Original languageEnglish
    Title of host publicationInduced Pluripotent Stem (iPS) Cells: Methods and Protocols
    EditorsKursad Turksen, Andras Nagy
    PublisherHumana Press
    Pages415-421
    Number of pages7
    Volume1357
    ISBN (Electronic)978-1-4939-3055-5
    ISBN (Print)978-1-4939-3054-8
    DOIs
    Publication statusPublished - 1 Jan 2016

    Publication series

    NameMethods in Molecular Biology

    Fingerprint

    Dive into the research topics of 'Enhancing human cardiomyocyte differentiation from induced pluripotent stem cells with trichostatin A'. Together they form a unique fingerprint.

    Cite this